Home HOME Neoplasma 2015 Neoplasma Vol.62, No.1, p.124-129, 2015

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.62, No.1, p.124-129, 2015

Title: Serum CYFRA21-1 as an effective tumor biomarker for patients with nasopharyngeal carcinoma
Author: X. M. SONG, S. Z. WANG, Z. J. WANG, W. J. CAO, J. L., F. CHEN


We investigated if the serum cytokeratin 19 fragment 21.1 (CYFRA21-1) level was elevated in nasopharyngeal carcinoma (NPC) and can function as a biomarker for detection and monitoring of NPC.

Three hundred and one study subjects were divided into two groups: the NPC group (n=126) and healthy control group (n=175).

Serum CYFRA21-1 levels were measured before and after treatment using a chemiluminescent immunoassay, and its association with tumor stage and the clinical objective responses were analyzed. Receiver operating characteristic (ROC) curve analysis was performed to discriminate patients with NPC from the healthy controls.

The pretreatment serum CYFRA21-1 level was significantly elevated in patients with NPC compared with the healthy controls (5.07±1.98 ng/ml vs 2.36±1.21 ng/ml, p<0.001), and it declined significantly after the entire treatment (2.14±0.72 ng/ml, p<0.001).

The serum CYFRA21-1 level of patients with a classification of T3-4 was significantly higher than that of those with class T1-2 (5.64±2.23 ng/ml vs 4.62±1.64 ng/ml, p=0.006), and that of patients with clinical stage III-IV was higher than clinical stage I-II (5.31±2.02 vs 4.04±1.37 ng/ml, p=0.003).

The AUC, sensitivity and specificity of elevated serum CYFRA21-1 in patients with NPC was 0.91, 0.83 and 0.89 respectively. In conclusion, the serum CYFRA21-1 level could be a reliable and effective biomarker for the detection and monitoring of NPC tumor progression.

Keywords: nasopharyngeal carcinoma, CYFRA21-1, tumor biomarker, receiver operating characteristic curve
Published online: 17-Oct-2014
Year: 2015, Volume: 62, Issue: 1 Page From: 124, Page To: 129

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.